Economic evaluation shows adding vancomycin does not improve outcomes in arthroplasty, suggesting cost savings by omitting it.
Adding vancomycin to cephazolin prophylaxis in arthroplasty is most likely not cost-effective. Omitting vancomycin could lead to substantial annual savings for the healthcare sector without compromising health outcomes.
No takes yet. Share an insight, caveat, or question.
Tran-Duy et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: